Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
Ranjeet Ajmani, Chief Executive Officer- Asia at Aegros, shared on LinkedIn:
”Plasma-Derived Medicinal Products (PDMPs) are life-saving therapies used to treat a wide range of medical conditions, including immune deficiencies, bleeding disorders, and various rare diseases.
These products are derived from human plasma, which can be collected in two ways: by separating it from donated whole blood (Recovered Plasma) or through a dedicated plasma donation process (Source Plasma).
The manufacturing of PDMPs involves a highly specialized and strictly regulated process called plasma fractionation, where different plasma proteins are separated and purified for therapeutic use.
Since plasma is the primary raw material for these products, ensuring its high quality and safety is of utmost importance.”
Stay informed on all coming webinars and seminars in Hematology with Hemostasis Today.
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 13, 2025, 09:54Cihan Ay: ISTH 2026 In Planning!
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 11, 2025, 15:42The True Price of Gene Therapy: Breaking Down Beqvez’s $3.5M Cost and What Really Drives It
-
Sep 13, 2025, 10:36Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
-
Sep 13, 2025, 09:44Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
-
Sep 13, 2025, 01:37Flora Peyvandi on Iron Deficiency in Mild to Moderate Bleeding Disorders
-
Sep 12, 2025, 07:28Lauren Murphy: Platelets as DNA “Sponges”
-
Sep 12, 2025, 03:38Haematologica Early View: Omid Seidizadeh Explores Genetics Behind Clinical Variability in Type 2 VWD
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 12, 2025, 07:54Aurelio Maggio Thanks Contributors to Webinar on Advanced Treatments in Rare Blood Disorders
-
Sep 12, 2025, 07:20Women for Their Health: Paige Bingham on Boston Scientific's Initiative ''Close the Gap'' Act During AFib Awareness Month
-
Sep 11, 2025, 15:27Postpartum Haemorrhage: In Kenya, More than 120 Mothers Die for Every 100,000 Live Births